Industry Overview

China prostate cancer diagnosis & treatment market was valued at $2,276.9 million in 2025 and is projected to reach $5,906.0 million by 2035, growing at a CAGR of 10.0% during the forecast period (2026-2035). The market expanding on account of the rising incidence of prostate malignancies, supported by demographic ageing and improved disease awareness. Increasing adoption of advanced screening modalities, including PSA testing and multiparametric imaging, is enabling earlier detection and timely clinical intervention. Government-led healthcare reforms and sustained investments in tertiary care infrastructure have strengthened access to oncology services across urban centers. In parallel, the entry of novel hormonal therapies, targeted agents, and precision radiopharmaceuticals has enhanced treatment outcomes and broadened the therapeutic landscape. Continued emphasis on clinical research, technology transfer, and domestic biopharmaceutical innovation is expected to reinforce market momentum over the forecast period.

Market Dynamics

Rising Disease Burden and Expansion of Diagnostic Infrastructure

Rapid demographic ageing and a rising incidence of prostate malignancies are increasing demand for diagnostic services and therapeutic interventions across China. Expansion of organized screening programs and greater uptake of prostate-specific antigen testing and multiparametric imaging are driving earlier diagnosis and higher diagnostic throughput. Investment in tertiary care facilities and regional oncology centers has improved access to advanced urological and radiology services. Strengthened referral pathways and multidisciplinary care protocols are enabling prompt initiation of definitive treatment. Enhanced public and physician awareness of prostate health is raising rates of health-seeking behaviour and elective screening. Growth in private-sector diagnostic providers is expanding capacity for advanced molecular and imaging assays. Regulatory streamlining for diagnostic approvals is accelerating the availability of novel clinical tests. Rising patient willingness to pursue specialist care supports sustained growth in diagnostic volumes and associated service lines.

Therapeutic Innovation and Strengthening Treatment Access Framework

Advances in therapeutic options, including next-generation hormonal agents, targeted therapies, precision radiopharmaceuticals, and minimally invasive focal treatments, are broadening clinical pathways and increasing treatment uptake. Greater domestic investment in biopharmaceutical R&D and strategic licensing agreements with international developers are accelerating product launches and local manufacturing. Expansion of clinical trial activity within the country is improving access to investigational agents and generating real-world evidence that informs clinical guidelines. Progressive inclusion of oncology therapies in public and commercial reimbursement schemes is reducing out-of-pocket burden and supporting market penetration. Strengthening distribution networks and partnerships between hospitals and specialty pharmacies are ensuring more reliable supply of high-value medicines. Provider training programs and guideline dissemination are facilitating adoption of novel treatment protocols. Competitive pricing strategies by both multinational and local companies are improving affordability and extending treatment access across a broader patient base.

Market Segmentation

• Based on diagnostic technique, the market is segmented into prostate-specific antigen test and digital rectal exam.
• Based on therapy, the market is segmented into hormonal therapy, chemotherapy, immunotherapy, radiation therapy, and targeted therapy.

PSMA-Targeted Radioligand Therapy: Rapidly Ascending Therapeutic Class

Targeted radioligand therapy has emerged as the fastest expanding therapeutic subsegment, driven by positive late-stage trial results and regulatory approvals for agents addressing PSMA-positive disease. Industry leaders such as Novartis have accelerated commercial rollout and investigator-initiated studies, while local clinical trial activity is increasing access to these treatments. Key growth factors include demonstrated survival benefits in advanced disease, improving nuclear medicine infrastructure, and strategic partnerships that enhance isotope supply and logistics. Market trends show expanding indications into earlier disease settings, rising inclusion in reimbursement discussions, and heightened interest from both multinational and domestic developers. Service providers are scaling multidisciplinary care pathways to manage patient selection, dosimetry and follow-up.

High-Volume PSA Assays: Core Diagnostic Segment

Prostate-specific antigen testing remains the primary diagnostic volume driver, sustained by routine screening protocols and high throughput laboratory networks. Demand growth is supported by expanding primary care referral pathways and greater availability of standardised assay platforms from major diagnostics suppliers such as Roche and Abbott Laboratories. Recent trends include migration to automated immunoassay systems, integration of reflex testing algorithms, and uptake of laboratory information systems that shorten turnaround times. Commercial dynamics reflect steady unit volumes with modest margin pressure from price reforms and procurement policies in the Chinese diagnostics market. Private diagnostic chains and hospital-owned laboratories are investing in capacity to meet rising outpatient testing demand. Policy initiatives that strengthen cancer screening pathways will sustain baseline assay volumes over the forecast interval.

Market Players Outlook

The major companies operating in the China prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., F. Hoffmann-La Roche AG, Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In January 2026, China’s regulatory authority accepted the new drug application for illuccix, a PSMA-targeted PET imaging agent that showed a high positive predictive value in detecting recurrent or metastatic prostate cancer in Chinese patients. This represents a significant step for PSMA-based precision diagnostics in China’s prostate cancer care landscape.
• In January 2026, Chinese nuclear medicine company XTR020 achieved successful results in its Phase III clinical trial for a novel radiopharmaceutical diagnostic for prostate cancer. The company plans to submit data to the National Medical Products Administration (NMPA) for approval, underscoring growing innovation capability in China’s imaging and theranostics space.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the China prostate cancer diagnostic and therapeutic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.